Early Administration of Recombinant Erythropoietin (RHEPO) in Transfusion Savings in Trauma Patients

Early Administration of Recombinant Erythropoietin (RHEPO) in Transfusion Savings in Trauma Patients

The objective of our study is to demonstrate the interest of early administration of recombinant erythropoietin in trauma patients

Could an early use of rHuEPO (recombinant Human ErythroPOietin ) be lead to an individual benefice on transfusion savings after traumatic surgery?

Inclusion Criteria:

• Patients between 18 to 65 years old
• Patient with an ASA 1 or 2 (ASA 1 corresponding to a patient in perfect health and ASA 2 to a patient with moderate involvement and well controlled organ function)
• patient presenting at least one of the following fractures: Basin and / or femur with surgical indication, associated or not with other fractures.
• patient with hemoglobin between 9 and 13 g / dl at the time of admission on trauma department

Exclusion Criteria:

• patient with contraindication to synthetic erythropoietin
• Patient with intravenous iron contraindication
• pregnant patient or with a risk of pregnancy
• patient who has not given his consent or does not understand the protocol
• Patient with hemodynamic instability
• patient participating in another research protocol for less than 3 months.